Abstract 5942
Background
Fatigue represents a complex and frequent symptom in cancer patients and influences their quality of life. Although nurses consider the initial evaluation of the patient to be fundamental, this problem is underestimated in clinical practice and often leads to under-treatment. In addition, the patients and their families still often do not report the symptom because they fear that it will lead to a reduction or suspension of treatment or they think that the symptom is inevitable.
Methods
Mixed methods study. Data were collected using Brief Fatigue Inventory, patients’ interviews, focus groups with nurses and analysis of patients’ records. The setting is represented by two impatient departments of Oncology Institute of Southern Switzerland. Quantitative data were analysed with SPSS 22.0. For the interviews and focus groups, the analysis processes were conducted according to conventional content analysis using Nvivo 10 software.
Results
71 questionnaires were analysed, 39 males and 32 females. The mean age was 65,7±14 years. Fatigue was reported 5 times (7%) in nursing documents and 17 times problems fatigue was reported by nurses 5 times (7%) in patients’ records, while in 17 cases (23.9%) related problems were reported. 12 patients were interviewed. Five themes were identified: feeling powerless and aggressive, my strategies or what helps me, feeling reassured by the presence of family members, feeling reassured by nurses’ gesture, to be informed. Three themes were identified from nurses focus group: objectivity and subjectivity in the assessment of asthenia, nursing contribution in the multidisciplinary management of asthenia and difficulty in evaluating outcomes.
Conclusions
A not systematic approach to the management of fatigue emerges. Patients are satisfied with the care received but would like more information and specific interventions. Quantitative and qualitative results seem converge. Fatigue is still an underestimated problem in clinical practice. Specific training interventions for health professionals are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific Research Advisory Board (ABREOC).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2743 - The Impact of Targeted Therapies and Immunotherapy in Melanoma Brain Metastases: a Systematic Review and Meta-Analysis
Presenter: Mario Mandala
Session: Poster Display session 3
Resources:
Abstract
5479 - Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis
Presenter: Jose Lutzky
Session: Poster Display session 3
Resources:
Abstract
3560 - Outcomes of Patients with Melanoma Brain Metastases (MBM) Treated with Standard of Care Therapy After Being Excluded from MBM-Specific Clinical Trials
Presenter: Kourtney Holbrook
Session: Poster Display session 3
Resources:
Abstract
3175 - The analysis of current treatment outcomes in melanoma patients with brain metastases
Presenter: Joanna Placzke
Session: Poster Display session 3
Resources:
Abstract
4550 - A multivariate model to define prognostic groups among patients with melanoma brain metastases: a 10-year retrospective cohort study
Presenter: Giacomo Pelizzari
Session: Poster Display session 3
Resources:
Abstract
4191 - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.
Presenter: Robert Ferguson
Session: Poster Display session 3
Resources:
Abstract
1625 - Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment
Presenter: Kenji Yokota
Session: Poster Display session 3
Resources:
Abstract
5346 - Evaluating polygenic risk score prediction model for melanoma prognosis
Presenter: Miriam Potrony
Session: Poster Display session 3
Resources:
Abstract
5477 - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy
Presenter: Maria Grazia Vitale
Session: Poster Display session 3
Resources:
Abstract
3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.
Presenter: Celine Boutros
Session: Poster Display session 3
Resources:
Abstract